Literature DB >> 22966326

The human pluripotency gene NANOG/NANOGP8 is expressed in gastric cancer and associated with tumor development.

Jingyu Zhang1, Xia Wang, Bing Chen, Zhifeng Xiao, Wenmei Li, Youyong Lu, Jianwu Dai.   

Abstract

It is well known that cancer cells exhibit characteristics similar to normal stem cells. The majority of tumors frequently overexpress genes commonly found in embryonic stem cells. To determine whether the pluripotency gene NANOG and its retrogene, NANOGP8, play a role in gastric cancer, we analyzed the NANOG/NANOGP8 expression profile at the mRNA and protein level in primary gastric tumors. Our data demonstrated that overexpression of NANOG/NANOGP8 was consistently detected in primary tumors (75%, 30/40) compared to adjacent normal tissues (12.5%, 5/40). Furthermore, NANOG/NANOGP8 was highly expressed in the intestinal metaplasia (60%, 24/40) and dysplasia tissues (66.7%, 20/30) compared to normal tissues. These results suggest that NANOG/NANOGP8 exhibits potential as a biomarker and its expression may play an important role in gastric cancer development.

Entities:  

Year:  2010        PMID: 22966326      PMCID: PMC3436456          DOI: 10.3892/ol_00000081

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  30 in total

1.  NANOGP8 is a retrogene expressed in cancers.

Authors:  Jingyu Zhang; Xia Wang; Meixiang Li; Jin Han; Bing Chen; Bin Wang; Jianwu Dai
Journal:  FEBS J       Date:  2006-04       Impact factor: 5.542

2.  Functional expression cloning of Nanog, a pluripotency sustaining factor in embryonic stem cells.

Authors:  Ian Chambers; Douglas Colby; Morag Robertson; Jennifer Nichols; Sonia Lee; Susan Tweedie; Austin Smith
Journal:  Cell       Date:  2003-05-30       Impact factor: 41.582

Review 3.  Pseudogenes: are they "junk" or functional DNA?

Authors:  Evgeniy S Balakirev; Francisco J Ayala
Journal:  Annu Rev Genet       Date:  2003       Impact factor: 16.830

Review 4.  Stem cell relationships and the origin of gastrointestinal cancer.

Authors:  Stefanie Schier; Nicholas A Wright
Journal:  Oncology       Date:  2005-09-19       Impact factor: 2.935

5.  Global cancer statistics, 2002.

Authors:  D Max Parkin; Freddie Bray; J Ferlay; Paola Pisani
Journal:  CA Cancer J Clin       Date:  2005 Mar-Apr       Impact factor: 508.702

6.  Stem-like cells in bone sarcomas: implications for tumorigenesis.

Authors:  C Parker Gibbs; Valery G Kukekov; John D Reith; Olga Tchigrinova; Oleg N Suslov; Edward W Scott; Steven C Ghivizzani; Tatyana N Ignatova; Dennis A Steindler
Journal:  Neoplasia       Date:  2005-11       Impact factor: 5.715

Review 7.  Gastric cancer stem cells.

Authors:  Shigeo Takaishi; Tomoyuki Okumura; Timothy C Wang
Journal:  J Clin Oncol       Date:  2008-06-10       Impact factor: 44.544

8.  An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors.

Authors:  Ittai Ben-Porath; Matthew W Thomson; Vincent J Carey; Ruping Ge; George W Bell; Aviv Regev; Robert A Weinberg
Journal:  Nat Genet       Date:  2008-05       Impact factor: 38.330

9.  Connexin43 pseudogene is expressed in tumor cells and inhibits growth.

Authors:  Mustapha Kandouz; Andrew Bier; George D Carystinos; Moulay A Alaoui-Jamali; Gerald Batist
Journal:  Oncogene       Date:  2004-06-10       Impact factor: 9.867

10.  Human embryonic genes re-expressed in cancer cells.

Authors:  M Monk; C Holding
Journal:  Oncogene       Date:  2001-12-06       Impact factor: 9.867

View more
  17 in total

Review 1.  NANOG expression in human development and cancerogenesis.

Authors:  Gašper Grubelnik; Emanuela Boštjančič; Ana Pavlič; Marina Kos; Nina Zidar
Journal:  Exp Biol Med (Maywood)       Date:  2020-02-10

Review 2.  NANOG: a promising target for digestive malignant tumors.

Authors:  Ai-Xi Sun; Chang-Jiang Liu; Zi-Qin Sun; Zhi Wei
Journal:  World J Gastroenterol       Date:  2014-09-28       Impact factor: 5.742

3.  An expressed retrogene of the master embryonic stem cell gene POU5F1 is associated with prostate cancer susceptibility.

Authors:  Joan P Breyer; Daniel C Dorset; Travis A Clark; Kevin M Bradley; Tiina A Wahlfors; Kate M McReynolds; William H Maynard; Sam S Chang; Michael S Cookson; Joseph A Smith; Johanna Schleutker; William D Dupont; Jeffrey R Smith
Journal:  Am J Hum Genet       Date:  2014-02-27       Impact factor: 11.025

4.  The pluripotency factor nanog promotes breast cancer tumorigenesis and metastasis.

Authors:  X Lu; S J Mazur; T Lin; E Appella; Y Xu
Journal:  Oncogene       Date:  2013-06-17       Impact factor: 9.867

5.  Expression of cancer stem cell marker during 4-nitroquinoline 1-oxide-induced rat tongue carcinogenesis.

Authors:  Wonbong Lim; Hongran Choi; Jisun Kim; Sangwoo Kim; Sangmi Jeon; Kou Ni; Sung-Yong Song; Hee-Kyun Oh; Yeonggwan Im; Gwangchul Lee; Jun Young Lee; Young Lae Moon; Jae Won You; Okjoon Kim
Journal:  J Mol Histol       Date:  2014-07-08       Impact factor: 2.611

Review 6.  ZNF281/ZBP-99: a new player in epithelial-mesenchymal transition, stemness, and cancer.

Authors:  Stefanie Hahn; Heiko Hermeking
Journal:  J Mol Med (Berl)       Date:  2014-05-18       Impact factor: 4.599

Review 7.  Emerging role of nanog in tumorigenesis and cancer stem cells.

Authors:  Luis E Iv Santaliz-Ruiz; Xiujie Xie; Matthew Old; Theodoros N Teknos; Quintin Pan
Journal:  Int J Cancer       Date:  2014-01-13       Impact factor: 7.396

8.  CRISPR/Cas9-mediated gene knockout of NANOG and NANOGP8 decreases the malignant potential of prostate cancer cells.

Authors:  Norihiko Kawamura; Keisuke Nimura; Hiromichi Nagano; Sohei Yamaguchi; Norio Nonomura; Yasufumi Kaneda
Journal:  Oncotarget       Date:  2015-09-08

Review 9.  Pluripotency transcription factors and cancer stem cells: small genes make a big difference.

Authors:  Anfei Liu; Xiya Yu; Shanrong Liu
Journal:  Chin J Cancer       Date:  2013-02-19

10.  NANOGP8: evolution of a human-specific retro-oncogene.

Authors:  Daniel J Fairbanks; Aaron D Fairbanks; T Heath Ogden; Glendon J Parker; Peter J Maughan
Journal:  G3 (Bethesda)       Date:  2012-11-01       Impact factor: 3.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.